CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 11, 2006, Pages 1066-1072

  Yuan, Sheng Hua ^a   Dai, De Zai ^a   Guan, Li ^a   Dai, Yin ^a   Ji, Min ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Endothelin receptor antagonists; Endothelin 1; Hypoxia; Pulmonary hypertension; Reactive oxygen species

Indexed keywords

CPU 0507; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYPROLINE; MALONALDEHYDE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; HEART WEIGHT; HEMODYNAMICS; HYPOXIA; IN VITRO STUDY; IN VIVO CULTURE; LUNG ARTERY PRESSURE; LUNG HOMOGENATE; MALE; NONHUMAN; OXIDATIVE STRESS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; HEART; HYPERTENSION, PULMONARY; MALE; MOLECULAR STRUCTURE; MYOCARDIUM; NIFEDIPINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; THIADIAZOLES; VASOCONSTRICTION; VASODILATION;

EID: 33750046289     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04488.x     Document Type: Article

References (25)

1. Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med. 1997; 336: 111-17.
2. Cohen H, Chahine C, Hui A et al. Bosentan therapy for pulmonary arterial hypertension. Am. J. Health Syst. Pharm. 2004; 61: 1108-9.
3. Xu FP, Chen MS, Wang YZ et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75.
4. MacLean MR. Endothelin-1: A mediator of pulmonary hypertension? Pulmon. Pharmacol. Ther. 1998; 11: 125-32.
5. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann. Pharmacol. Ther. 2003; 37: 1055-62.
6. Liu L-G. Synthesis of non peptide endothelin receptor antagonists and their structures and structure activity relationships studies. PhD thesis, China Pharmaceutical University, Nanjing, China. 2002.
7. B of compound 0213. J. Chin. Pharm. Univ. 2004; 35: 552-7.
8. max and elevation of verapamil in L-thyroxin induced hypertrophied guinea pig ventricular membrane. Chin. Pharmacol. Bull. 2003; 19: 294-8 (in Chinese).
9. BR). J. Chin. New Drugs 2006 (in press).
10. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2006; 3: CD004434.
11. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp. Biol. Med. 2006; 231: 967-73.
12. Zhang TT, Cui B, Dai DZ et al. Pharmacological efficacy of CPU86017 on hypoxic pulmonary hypertension in rats. J. Cardiovasc. Pharmacol. 2005; 46: 727-34.
13. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 2002; 85: 195-7.
14. Corno AF, Milano G, Samaja M et al. Chronic hypoxia: A model for cyanotic congenital heart defects. J. Thorac. Cardiovasc. Surg. 2002; 124: 105-12.
15. Yang P, Dai DZ. L-Thyroxine-induced vasodilation impairment and increased vascular response to norepinephrine are mediated by dysfunctional NO release. Drug Dev. Res. 2003; 58: 116-21.
16. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: A model for what human disease? J. Clin. Invest. 2000; 106: 733-8.
17. Vieillard-Baron A, Frisdal E, Eddahibi S et al. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ. Res. 2000; 87: 418-25.
18. Chen LN, He H, Mondejar EF et al. Endothelin-1 and nitric oxide synthase in short rebound reaction to short exposure to inhaled nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H124-31.
19. Li ZC, Zhang FQ, Song JC et al. Therapeutic effects of DCDDP, a calcium channel blocker, on chronic pulmonary hypertension in rat. J. Appl. Physiol. 2002; 92: 997-1003.
20. Fike CD, Kaplowitz MR. Nifedipine inhibits pulmonary hypertension but does not prevent decreased lung eNOS in hypoxic newborn pigs. Am. J. Physiol. 1999; 277: L449-56.
21. McGinty A, Scholfield CN, Liu WH et al. Effect of glucose on endothelin-1-induced calcium transients in cultured bovine retinal pericytes. J. Biol. Chem. 1999; 274: 25 250-3.
22. 2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes. J. Physiol. 1992; 448: 729-47.
23. Dlugosz JA, Munk S, Zhou XP et al. Endothelin-1-induced mesangial cell contraction involves activation of protein kinase C-α, -δ and -ε. Am. J. Physiol. 1998; 275: F423-32.
24. 2+ current in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch. Pharmacol. 1999; 360: 654-64.
25. Zhang TT, Cui B, Dai DZ et al. CPU 86017, p-chloro-benzyl- tetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway 1. Acta Pharmacol. Sin. 2005; 26: 1309-16.